Screener
Avalo Therapeutics AVTX License and milestones
License and milestones at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:AccruedLicenseAndMilestonesCurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | As of / June 30, 2026 | As of / December 31, 2025 |
|---|---|---|
| Research and development | $3,576 | $7,270 |
| License and milestones | 10,000 | — |
| Compensation and benefits | 2,805 | 4,132 |
| General and administrative | 1,160 | 682 |
| Royalty payment | — | 327 |
| Lease liability, current | 242 | 392 |
| Total accrued expenses and other current liabilities | $17,783 | $12,803 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's license and milestones?
- Avalo Therapeutics (AVTX) reported license and milestones of $10M in Q2 2026.
- What does license and milestones mean?
- License and milestones as reported by Avalo Therapeutics, Inc. Common Stock.
Ask your AI about Avalo Therapeutics's license and milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude